CT-0525

N/A

Report date: 2024/12/19 10:48:57

Base Information

Drug NameCT-0525

Drug Alias NameCT-0525

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapy > Chimeric antigen receptor Monocyte Therapy

Mechanisms of ActionCell replacementsImmunologic cytotoxicityReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCarisma Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCarisma Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A